Aileron Therapeutics, Inc.
ALRN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $119 | $169 | $121 |
| Gross Profit | $0 | -$119 | -$169 | -$121 |
| % Margin | – | – | – | – |
| R&D Expenses | $14,248 | $3,991 | $17,967 | $17,008 |
| G&A Expenses | $13,864 | $11,357 | $9,680 | $9,597 |
| SG&A Expenses | $13,864 | $11,357 | $9,680 | $9,597 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $37,000 | $928 | $0 | $0 |
| Operating Expenses | $65,112 | $16,276 | $27,647 | $26,605 |
| Operating Income | -$65,112 | -$16,276 | -$27,647 | -$26,605 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2,229 | $544 | $318 | $441 |
| Pre-Tax Income | -$62,883 | -$15,732 | -$27,329 | -$26,205 |
| Tax Expense | $0 | $0 | $0 | -$441 |
| Net Income | -$62,883 | -$15,732 | -$27,011 | -$25,764 |
| % Margin | – | – | – | – |
| EPS | -3.51 | -3.42 | -5.95 | -5.8 |
| % Growth | -2.6% | 42.5% | -2.6% | – |
| EPS Diluted | -3.51 | -3.42 | -5.95 | -5.8 |
| Weighted Avg Shares Out | 17,939 | 4,599 | 4,539 | 4,440 |
| Weighted Avg Shares Out Dil | 17,939 | 4,599 | 4,539 | 4,440 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $119 | $169 | $121 |
| EBITDA | -$65,112 | -$15,613 | -$27,478 | -$26,484 |
| % Margin | – | – | – | – |